Oligometastases.

Hellman, Samuel; Weichselbaum, Ralph R.

doi:10.1200/jco.1995.13.1.8

Cited by 2,069 publications

(1,034 citation statements)

References 0 publications

Supporting

Mentioning

920

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, this improves overall survival for only a few months [2,4]. However, 7 % of patients with metastatic disease only suffer from a single metastasis; in 1995, Hellman and Weichselbaum introduced the term "oligometastatic" for this special subgroup of patients [5,6]. These patients may benefit from surgical resection of the primary tumor and its metastasis.…”

Section: Introductionmentioning

confidence: 99%

Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer

et al. 2012

View full text Add to dashboard Cite

The prognosis of metastatic non-small cell lung cancer (NSCLC) is poor, and platinum-based chemotherapy improves the median survival for only a few months. A subgroup of patients with oligometastatic disease may benefit from surgical resection, but only very limited data are available to date. We conducted a retrospective review of all patients with synchronous extrapulmonary oligometastatic NSCLC undergoing surgical resection in our department. Data regarding medical history, histology, number of metastases, and survival status were extracted from the medical database

show abstract

Section: Introductionmentioning

confidence: 99%

Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…This hypothesis is still widely accepted. Observing the natural history of breast cancer, Hellmann and Weichselbaum hypothesized the existence of an intermediate state between widespread metastatic disease and locally confined disease and coined the term "oligometastases" (Hellman & Weichselbaum, 1995). Thus, local control of oligometastatic disease may allow better systemic control.…”

Section: Definitionmentioning

confidence: 99%

Curative Radiotherapy in Metastatic Disease: How to Develop the Role of Radiotherapy from Local to Metastases

Kay¹,

Kang²

2013

Frontiers in Radiation Oncology

View full text Add to dashboard Cite

“…In 1995 Hellman S and Weichselbaum RR proposed to introduce the term "oligometastases" as metastases concentrated in single or limited number of organs [4]. They suggested that the likelihood of the oligometastatic state can correlate with the biology of tumour progression.…”

mentioning

confidence: 99%

“…They suggested that the likelihood of the oligometastatic state can correlate with the biology of tumour progression. Tumours which are early in the chain of progression may have not fully developed the facility for metastatic growth [3,4]. The consequence of the oligometastatic disease is that some patients fit the curative therapeutic strategy [3,4,5].…”

mentioning

confidence: 99%

See 1 more Smart Citation

CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.

Napieralska¹,

Miszczyk²,

Stąpór-Fudzińska³

2016

neo

View full text Add to dashboard Cite

The aim of the study was to evaluate the effectiveness and toxicity of CyberKnife (CK) stereotactic radiosurgery (SRS) and stereotactic ablative radiation therapy (SABR) of patients with prostate cancer bone metastases. Analysis of prognostic and predictive factors was also performed.Material consisted of 51 patients with 71 bone oligometastases treated using CK SRS/SABR. In half of the patients single lesion was treated, in half 2-5 lesions. Median PSA concentration at the time of metastasis detection was 5.75 ng/ml. Total dose of 6-45Gy (median 20) was delivered with 1-5 fractions of 6-15 Gy (median 9). Biologic equivalent dose (BED) (α/ β=1.6) over 100 Gy was delivered to 45 lesions (63%) in 38 patients (75%).In statistical analysis Kaplan-Meier method, log-rank test and the Cox proportional hazard model were used. One-, two-and three-year overall survival (OS) was 90%, 76% and 70%, respectively. All patients having PSA concentration lower that 1 ng/ml at last control lived at least three years. One-, two-and three-year local control (LC) was 97%, 70% and 30%. Patients with PSA below 20 ng/ml at the time of metastasis detection had better local control of lesions and lower PSA at the last control. Median of PSA concentration after CK based SRS/SABR remains stable during first 12 months of follow-up, dropped during the next months and at last control was comparable to initial level. Median PSA at last control in patients without disease progression was 1.67ng/ml and 20 patients had PSA below 1.0ng/ml. At the last control 59% of patients had no other metastases. Rapid pain decrease was observed in analysed group and during each control about 90% of patients had pain relief. No major toxicity was observed, 3 patients suffered from fracture of irradiated bone. SRS/SABR of prostate cancer bone oligometastases provides good LC of lesions, excellent pain control without additional toxicity. Patients with PSA concentration below 20ng/ml at the time of metastasis detection have better LC and PSA concentration response.

show abstract

Oligometastases.

Cited by 2,069 publications

References 0 publications

Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer

Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer

Curative Radiotherapy in Metastatic Disease: How to Develop the Role of Radiotherapy from Local to Metastases

CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.

Contact Info

Product

Resources

About